After Lumos Pharma reported interim results from OraGrowtH210 and 212, Piper Sandler analyst Yasmeen Rahimi said AHV came in as expected, but it was lower than the rhGH arm. While two outliers in the OraGrowtH210 rhGH cohort impacted the stock, Rahimi is "not concerned about this for the full population" and believes this readout de-risks LUM-201 heading into full results in the second half of 2023. Rahimi, who argues that the interim results "validate LUM-201 as an oral therapy for PGHD," keeps an Overweight rating and $26 price target on Lumos shares, which closed $3.09, or 35%, lower on Monday at $5.82.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LUMO: